Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope.
Perkins Coie LLP, Washington, DC, USA. csandercock@perkinscoie.com
Colin G
CG
Sandercock
Ulrich
U
Storz
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D000939:Epitopes / Q000276:immunology; D006801:Humans; D007603:Jurisprudence; D010330:Patents as Topic; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000939:Epitopes; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab